Condition
Fibrillary Glomerulonephritis
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 4 (2)
Trial Status
Completed2
Recruiting2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06295770Phase 2RecruitingPrimary
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
NCT06680349Phase 4CompletedPrimary
Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis
NCT06065852Recruiting
National Registry of Rare Kidney Diseases
NCT05546047Phase 4UnknownPrimary
A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients
NCT02197767Phase 2CompletedPrimary
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Showing all 5 trials